Spots Global Cancer Trial Database for Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Official Title: A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer
Study ID: NCT01348009
Conditions
Interventions
Study Description
Brief Summary: Cisplatin, an intravenously administered platinum agent, in combination with an intravenously administered taxane and capecitabine has been shown to improve time to disease progression and overall survival in previously untreated patients with gastric cancer. This study is being performed to evaluate an orally administered taxane (tesetaxel) in combination with cisplatin and capecitabine in previously untreated patients with gastric cancer.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, , Korea, Republic of
Contact Details
Name: Sun Young Rha, MD, PhD
Affiliation: Yonsei Cancer Center, Yonsei University College of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
